GENERIC STEP THERAPY PLANS (GSTP)

DRUG CLASS NASAL STEROIDS

PGST SSB: Beconase AQ, Omnaris, Qnasl, Ryaltris, Zetonna

HPGST SSB: Beconase AQ, Omnaris, Qnasl, Ryaltris, Zetonna

TGST SSB: Beconase AQ, Omnaris, Qnasl, Ryaltris, Zetonna

Status: CVS Caremark® Criteria

Type: Initial Step Therapy; Post Step Therapy Prior Authorization

POLICY

INITIAL STEP THERAPY

If the patient has filled a prescription for at least a 30 day supply of at least one brand or generic over-the-counter (OTC) nasal steroid or at least one generic prescription nasal steroid or at least one generic prescription nasal steroid combination product within the past 180 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

Authorization may be granted for the requested branded nasal steroid or branded nasal steroid combination when ONE of the following criteria are met:

- The patient has experienced an inadequate treatment response after at least a 30 day trial of at least ONE brand
 or generic over-the-counter (OTC) nasal steroid OR at least ONE generic prescription nasal steroid OR at least
 ONE generic prescription nasal steroid combination product
- The patient has a documented contraindication or a potential drug interaction that would prohibit a trial of at least ONE brand or generic over-the-counter (OTC) nasal steroid OR at least ONE generic prescription nasal steroid OR at least ONE generic prescription nasal steroid combination product
- The patient has experienced an intolerance to at least ONE brand or generic over-the-counter (OTC) nasal steroid OR at least ONE generic prescription nasal steroid OR at least ONE generic prescription nasal steroid combination product

DURATION OF APPROVAL (DOA)

4589-D: DOA: 24 months4590-D: DOA: 24 months4591-D: DOA: 24 months

REFERENCES

N/A

GSTP Nasal Steroids w_OTCs Policy 4589-D, 4590-D, 4591-D UDR 02-2024 rights reserved.

©2024 CVS Caremark. All